Vontobel Holding Ltd. Lowers Stock Position in Abbott Laboratories $ABT

Vontobel Holding Ltd. lowered its position in Abbott Laboratories (NYSE:ABT) by 32.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,384,193 shares of the healthcare product maker’s stock after selling 1,591,445 shares during the period. Abbott Laboratories comprises about 1.3% of Vontobel Holding Ltd.’s portfolio, making the stock its 19th largest position. Vontobel Holding Ltd.’s holdings in Abbott Laboratories were worth $424,006,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in ABT. First National Bank of Omaha increased its stake in shares of Abbott Laboratories by 15.2% during the 4th quarter. First National Bank of Omaha now owns 170,756 shares of the healthcare product maker’s stock worth $21,405,000 after purchasing an additional 22,526 shares during the last quarter. Alchemi Wealth LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $226,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Abbott Laboratories by 5.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,058,894 shares of the healthcare product maker’s stock worth $1,385,569,000 after purchasing an additional 602,415 shares during the last quarter. Van Lanschot Kempen Investment Management N.V. increased its stake in shares of Abbott Laboratories by 83.5% during the 4th quarter. Van Lanschot Kempen Investment Management N.V. now owns 188,796 shares of the healthcare product maker’s stock worth $23,654,000 after purchasing an additional 85,931 shares during the last quarter. Finally, Gator Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $3,612,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $87.89 on Friday. The company has a 50 day moving average of $91.46 and a 200 day moving average of $107.98. The stock has a market cap of $153.08 billion, a P/E ratio of 24.62, a P/E/G ratio of 1.50 and a beta of 0.63. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $139.06. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. Abbott Laboratories’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Insider Activity at Abbott Laboratories

In other news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction that occurred on Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average cost of $92.65 per share, with a total value of $926,500.00. Following the purchase, the director owned 6,751,103 shares of the company’s stock, valued at $625,489,692.95. This represents a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a research note on Wednesday, May 27th. Evercore reduced their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Benchmark reduced their target price on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Bank of America reduced their target price on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Daiwa Securities Group downgraded shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research note on Wednesday, April 22nd. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.38.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott declared its 410th consecutive quarterly dividend, underscoring its long track record of returning cash to shareholders. The board approved a 63-cent per share quarterly dividend. Abbott declares 410th consecutive quarterly dividend
• Positive Sentiment: Erste Group Bank nudged its FY2026 EPS estimate higher for Abbott, aligning with the current consensus of $5.48 per share, which suggests analysts still see stable earnings power.
• Positive Sentiment: Abbott also continues to highlight growth opportunities in diabetes care and medtech, including an expanded MiniMed collaboration and recent CE Mark approval for Libre Duo, supporting the company’s innovation story.
• Neutral Sentiment: Research coverage remains mixed, with one Seeking Alpha piece calling Abbott “structurally undervalued,” but this is opinion-based and not a direct catalyst. Abbott Laboratories Remains Structurally Undervalued
• Neutral Sentiment: Erste Group also trimmed its FY2027 EPS estimate slightly to $6.04 from $6.05, a very small revision that should have limited impact on sentiment.
• Neutral Sentiment: Star51 Capital’s first close of its medtech fund included Abbott as a lead backer, reinforcing Abbott’s strategic interest in healthcare innovation, though the direct stock impact is likely modest.
• Negative Sentiment: BofA cut its price target on Abbott from $120 to $102, signaling less upside than before and likely adding to investor caution. BofA adjusts price target on Abbott Laboratories to 102 from 120
• Negative Sentiment: Recent trading has shown Abbott slipping more than the broader market, reflecting ongoing weakness in the shares and investor concern over valuation versus slower near-term momentum. Abbott (ABT) Dips More Than Broader Market
• Negative Sentiment: Portfolio filings showing Elfun Trusts exited Abbott may also add a small amount of selling pressure, though this is not a major fundamental development. Elfun Trusts Exits Abbott Laboratories

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.